Your trusted destination for CME, CPD & Medical Education across the Middle East.
Barts and The London School of Medicine and Dentistry, Queen Mary University of London
Dr. Drew Provan is an internationally renowned emeritus academic, consultant hematologist, medical author, and clinical researcher who has spent over three decades shaping global diagnostic standards, therapeutic algorithms, and scientific consensus for autoimmune hematological disorders. He earned his undergraduate medical degree and Doctor of Medicine (MD) degree with high distinction, followed by structured postgraduate residency training in general internal medicine and clinical pathology. Driven to decipher the complex immune-mediated destruction of cellular blood components, he completed subspecialty fellowship training in academic hematology in the United Kingdom, earning Fellowships with both the Royal College of Physicians (FRCP, London) and the Royal College of Pathologists (FRCPath).
Holding long-standing academic and clinical appointments, Dr. Provan served as Reader in Autoimmune Hematology at Barts and The London School of Medicine and Dentistry, Queen Mary University of London (QMUL), while maintaining an active tertiary clinical practice as Consultant Hematologist at Barts Health NHS Trust. His specialized clinical and translational scope centers on autoimmune cytopenias, primarily primary immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), Evans syndrome, thrombotic microangiopathies, and iron deficiency disorders.
Throughout his distinguished career, Dr. Provan has been a chief international architect of evidence-based consensus guidelines that govern autoimmune hematology. Most notably, he served as the primary author and chairman of the landmark International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia,published across multiple revisions in Blood and Blood Advances, which serves as the gold-standard clinical reference for hematologists worldwide.
A major milestone of Dr. Provan’s professional legacy has been advocating for a paradigm shift in ITP management—moving away from toxic, non-specific immunosuppression and early splenectomy toward targeted receptor agonists and targeted immunomodulatory biologics. His clinical trials and advisory leadership have accelerated the global adoption of thrombopoietin receptor agonists (TPO-RAs, such as romiplostim, eltrombopag, and avatrombopag) and FcRn inhibitors,significantly improving long-term remission rates and quality of life for refractory patients.
In addition to his academic research leadership and hospital appointments, Dr. Provan is a celebrated medical educator,author, and digital health innovator. He has written and edited numerous foundational textbooks, including the widely acclaimed Oxford Handbook of Clinical Haematology and ABCs of Clinical Haematology, which have educated generations of medical students, residents, and practicing physicians globally. His teaching philosophy emphasizes structured diagnostic logic, critical evaluation of clinical evidence, and active patient empowerment.
Dr. Provan is an exceptionally prolific physician-scientist who has published over 200 peer-reviewed scientific studies,systematic reviews, and textbook chapters in premier journals, including The New England Journal of Medicine (NEJM),The Lancet, Blood, and British Journal of Haematology. His high-impact research portfolio focuses on elucidating the cellular mechanisms of platelet destruction, evaluating real-world efficacy of second-line ITP agents, mapping patient-reported outcome measures (PROMs) in chronic fatigue and bleeding, and integrating smartphone-based symptom tracking into clinical care.
Beyond his university leadership at QMUL, Dr. Provan actively serves on international advisory boards, consensus panels, and steering committees for major global organizations, including the European Hematology Association (EHA),the American Society of Hematology (ASH), and the ITP Support Association. He frequently represents the international hematology community as a plenary keynote presenter, course director, and panel chairperson at major global congresses across Europe, North America, Asia, and the Middle East.
At the International Classical Hematology Conference 2026 (ICCH 2026), Dr. Drew Provan stands out as a core scientific keynote presenter, masterclass director, and international co-chair. Connecting consultant hematologists, clinical researchers, laboratory scientists, and public health strategists, he provides delegates with cutting-edge, evidence-based tools to optimize autoimmune cytopenia management, adopt the latest international consensus guidelines, and elevate classical hematology practice standards nationwide and across the region.

MeetingMinds Experts
MeetingMinds Experts